2020

 

• Kalló, G., Kunkli, B., Győri, Z., Szilvássy, Z., Csősz, É., Tőzsér, J.Compounds with Antiviral, Anti-Inflammatory and Anticancer Activity Identified in Wine from Hungary’s Tokaj Region via High Resolution Mass Spectrometry and Bioinformatics Analyses.International Journal of Molecular Sciences (2020), 21, 9547.
• Miczi, M., Golda, M., Kunkli, B., Nagy, T., Tőzsér, J, Mótyán JA.Identification of Host Cellular Protein Substrates of SARS-COV-2 Main Protease.International Journal of Molecular Sciences (2020), 21(24), 9523.
• Mahdi, M., Mótyán, J.A., Szojka, Z.I., Golda, M., Miczi, M., Tőzsér, J.Analysis of the efficacy of HIV protease inhibitors against SARS-CoV-2′s main protease.Virology Journal (2020), 17, 190.
• Bozóki B, Mótyán JA, Hoffka G, Waugh DS, Tőzsér J.Specificity Studies of the Venezuelan Equine Encephalitis Virus Non-Structural Protein 2 Protease Using Recombinant Fluorescent Substrates.International Journal of Molecular Sciences (2020), 21(20), 7686.
• Szojka, Z., Mótyán, J.A., Miczi, M., Mahdi, M., Tőzsér, J.Y44A Mutation in the Acidic Domain of HIV-2 Tat Impairs Viral Reverse Transcription and LTR-Transactivation.International Journal of Molecular Sciences (2020), 21(16), 5907.
  
• Golda, M., Mótyán, J.A., Nagy, K., Matúz, K., Nagy, T., Tőzsér, J.*Biochemical Characterization of Human Retroviral-Like Aspartic Protease 1 (ASPRV1).Biomolecules (2020), 10 (7): 1004.
  
• Golda, M., Mótyán, J.A., Mahdi, M., Tőzsér, J.*Functional Study of the Retrotransposon-Derived Human PEG10 Protease.International Journal of Molecular Sciences (2020), 21(7): 2424.
• Mótyán, J.A., Miczi, M., Tőzsér, J.Dimer Interface Organization is a Main Determinant of Intermonomeric Interactions and Correlates with Evolutionary Relationships of Retroviral and Retroviral-Like Ddi1 and Ddi2 ProteasesInternational Journal of Molecular Sciences (2020) 21(4): 1352.
  
• Gazda, L.D., Joóné Matúz, K., Nagy, T., Mótyán, J.A.*, Tőzsér, J.*Biochemical characterization of Ty1 retrotransposon protease.PLoS ONE (2020) 15(1): e0227062.
  

2019

• Kassay, N., Mótyán, J.A. , Matúz, K., Golda, M., Tőzsér, J. Biochemical Characterization, Specificity and Inhibition Studies of HTLV-1, HTLV-2, and HTLV-3 Proteases.Life (2021), 11(2), 127.
• Mokánszki, A., Chang Chien, Y-C., Mótyán, J.A., Juhász, P., Bádon, E.S., Madar, L., Szegedi, I., Kiss, C., Méhes, G.Novel RB1 and MET Gene Mutations in a Case with Bilateral Retinoblastoma Followed by Multiple Metastatic Osteosarcoma.Diagnostics (2021), 11(1), 28.
• Diszházi, Gy., Magyar, Zs.E., Mótyán, J.A., Csernoch, L., Jóna, I., Nánási, P.P., Almássy, J.Dantrolene requires Mg2+ and ATP to inhibit the ryanodine receptorMolecular Pharmacology (2019) 96(3): 401-407
  
• Bozóki, B., Mótyán, J.A., Miczi, M., Gazda, L. D., Tőzsér, J. Use of Recombinant Fusion Proteins in a Fluorescent Protease Assay Platform and Their In-gel Renaturation.  J. Vis. Exp. (2019) (143), e58824

2018 

• Mahdi, M., Szojka, Zs., Mótyán, J.A., Tőzsér, J. Inhibitory Effects of HIV-2 Vpx on Replication of HIV-1. J Virol. (2018), 92, pii: e00554-18.
• Mótyán, J.A., Miczi, M., Bozóki, B., Tőzsér, J. Data supporting Ni-NTA magnetic bead-based fluorescent protease assay using recombinant fusion protein substrates.  Data in brief. (2018), 18: 203-208.
• Bozóki, B., Gazda, L., Tóth, F., Miczi, M., Mótyán, J.A., Tőzsér, J. A recombinant fusion protein-based, fluorescent protease assay for high throughput-compatible substrate screening.  Anal Biochem. (2018), 540-541: 52-63.
• Tőzsér J, Mótyán JA, Müller V. „Vírus proteázok” book chapter in „Ezerarcú fehérjék” book. (2018) ISBN: 9789633314586. Editors: Perczel A, Nyitray L, Buday L.
• Collaborative work awarded by “Bagossi Péter" publication award at University of Debrecen: Koczok, K., Merő, G., Szabó, G.P., Madar, L., Gombos, É., Ajzner, É., Mótyán, J.A., Hortobágyi, T., Balogh, I. A novel point mutation affecting Asn76 of dystrophin protein leads to dystrophinopathy. Neuromuscul Disord. (2018) pii: S0960-8966(17)30584-9.

2016

• Tóth, F., Kádas, J., Mótyán, J.A., Tőzsér, J. Effect of internal cleavage site mutations in human immunodeficiency virus type 1 capsid protein on its structure and function. FEBS Open Bio. 2016, 6(8):847-59.

2015

• M Mahdi, Z Szojka, JA Mótyán, J Tőzsér. Inhibition Profiling of Retroviral Protease  Inhibitors  Using an HIV-2 Modular System.Viruses, 2015

2014

• Mahdi M, Matúz K, Tóth F, Tőzsér J. A Modular System to Evaluate the Efficacy of Protease Inhibitors against HIV-2. PLoS ONE 2014, 9(11): e113221.

2013

• Mótyán JA, Tóth F, Tőzsér J. Research Applications of Proteolytic Enzymes in Molecular Biology.Biomolecules2013, 3: 923-942.
• Mótyán JA, Bagossi P, Benkő S, Tőzsér J. A molecular model of the full-length human NOD-like receptor family CARD domain containing 5 (NLRC5) protein BMC Bioinformatics 2013, 14 (1): 275.
• Torok Z, Peto T, Csosz E, Tukacs E, Molnar A, Maros-Szabo Z, Berta A, Tozser J, Hajdu A, Nagy V, Domokos B, Csutak A. Tear fluid proteomics multimarkers for diabetic retinopathy screening BMC ophthalmology 2013, 13 (1): 40.
• Varga A, Budai MM, Milesz S, Bácsi A, Tőzsér J, Benkő S. Ragweed pollen extract intensifies lipopolysaccharide-induced priming of NLRP3 inflammasome in human macrophages. Immunology, 2013, 138: 392-401.
• Louis JM, Tőzsér J, Roche J, Matúz K, Aniana A, Sayer JM. Enhanced stability of monomer fold correlates with extreme drug resistance of HIV-1 protease Biochemistry 2013, 52 (43): 7678-88.
• Budai MM, Varga A, Milesz S, Tőzsér J, Benkő S. Aloe vera downregulates LPS-induced inflammatory cytokine production and expression of NLRP3 inflammasome in human macrophages. Mol Immunol 2013, 56 (4): 471-9.
• Raran-Kurussi S, Tözsér J, Cherry S, Tropea JE, Waugh DS. Differential temperature dependence of tobacco etch virus and rhinovirus 3C proteases Analytical biochemistry 2013, 436 (2): 142-144.

2012

• János Harangi, Gabriella Béke, Mariann Harangi, János András Mótyán. Transglycosylation by barley α-amylase 1. Journal of Inclusion Phenomena and Macrocyclic Chemistry, Volume 73, Numbers 1-4, Pages 335-339, 2012.
• Li M, Gustchina A, Matúz K, Tözsér J, Namwong S, Goldfarb NE, Dunn BM, Wlodawer A. Structural and biochemical characterization of the inhibitor complexes of xenotropic murine leukemia virus-relate virus protease.FEBS J. 2011 Nov;278(22):4413-24.
• Adám C, Erdei E, Casado C, Kovács L, González A, Majoros L, Petrényi K, Bagossi P, Farkas I, Molnar M, Pócsi I, Ariño J, Dombrádi V. Protein phosphatase CaPpz1 is involved in cation homeostasis, cell wall integrity and virulence of Candida albicans. Microbiology. 2012 May;158(Pt 5):1258-67. Epub 2012 Feb 16.
• Matúz K, Mótyán J, Li M, Wlodawer A, Tőzsér J. Inhibition of XMRV and HIV-1 proteases by pepstatin Aand acetyl-pepstatin. FEBS J.2012 Sep;279(17):3276-86. doi: 10.1111/j.1742-4658.2012.08714.x. Epub 2012 Aug 17.
• Tie Y, Wang YF, Boross PI, Chiu TY, Ghosh AK, Tozser J, Louis JM, Harrison RW, Weber IT. Critical differences in HIV-1 and HIV-2 protease specificity for clinical inhibitors. Protein Sci. 2012 Mar;21(3):339-50. doi: 10.1002/pro.2019. Epub 2012 Jan 24.
• Csősz É, Boross P, Csutak A, Berta A, Tóth F, Póliska S, Török Z, Tőzsér J. Quantitative analysis of proteins in the tear fluid of patients with diabetic retinopathy. J Proteomics. 2012 Apr 3;75(7):2196-204. Epub 2012 Jan 26.

2011

• János A. Mótyán, Erika Fazekas,, Haruhide Mori, Birte Svensson, Péter Bagossi, Lili Kandra, Gyöngyi Gyémánt. Transglycosylation by barley α-amylase 1. Journal of Molecular Catalysis B: Enzymatic.Volume 72, Issues 3–4, November 2011
• Mótyán JA, Gyémánt G, Harangi J, Bagossi P. Computer-aided subsite mapping of α-amylases.Carbohydr Res. 2011 Feb 15;346(3):410-5. Epub 2010 Dec 9.

2010

• Tözsér J. Comparative studies on retroviral proteases: substrate specificity. Viruses. 2010 Jan;2(1):147-65. Epub 2010 Jan 14.
• Austin BP, Tözsér J, Bagossi P, Tropea JE, Waugh DS. The substrate specificity of Metarhizium anisopliae and Bos taurus carboxypeptidases A: insights into their use as tools for the removal of affinity tags.Protein Expr Purif. 2011 May;77(1):53-61. Epub 2010 Nov 10.
• Sun P, Austin BP, Tözsér J, Waugh DS. Structural determinants of tobacco vein mottling virus protease substrate specificity.Protein Sci. 2010 Nov;19(11):2240-51.
• Csutak A, Silver DM, Sperka T, Kádas J, Vereb G, Berta A, Tozsér J. Urokinase down-regulation by aprotinin in rabbit corneal cells after photorefractive keratectomy.Curr Eye Res. 2010 Sep;35(9):806-11.

2009

• Bagossi P, Bander P, Bozóki B, Tözsér J. Discovery and significance of new human T-lymphotropic viruses: HTLV-3 and HTLV-4.Expert Rev Anti Infect Ther. 2009 Dec;7(10):1235-49. Review.
• Kovács L, Alexa A, Klement E, Kókai E, Tantos A, Gógl G, Sperka T, Medzihradszky KF, Tözsér J, Dombrádi V, Friedrich P.Regulation of calpain B from Drosophila melanogaster by phosphorylation.FEBS J. 2009 Sep;276(17):4959-72. Epub 2009 Aug 4.
• Boross P, Bagossi P, Weber IT, Tözsér J. Drug targets in human T-lymphotropic virus type 1 (HTLV-1) infection.Infect Disord Drug Targets. 2009 Apr;9(2):159-71. Review.
• Zhang D, Tözsér J, Waugh DS. Molecular cloning, overproduction, purification and biochemical characterization of the p39 nsp2 protease domains encoded by three alphaviruses. Protein Expr Purif. 2009 Mar;64(1):89-97. Epub 2008 Oct 30.

2008

• Benko S, Tozser J, Miklossy G, Varga A, Kadas J, Csutak A, Berta A, Rajnavolgyi E. Constitutive and UV-B modulated transcription of Nod-like receptors and their functional partners in human corneal epithelial cells. Mol Vis. 2008 Aug 29;14:1575-83.
• Csosz E, Bagossi P, Nagy Z, Dosztanyi Z, Simon I, Fesus L. Substrate preference of transglutaminase 2 revealed by logistic regression analysis and intrinsic disorder examination. J Mol Biol. 2008 Nov 7;383(2):390-402. Epub 2008 Aug 22.
• Eizert H, Bander P, Bagossi P, Sperka T, Miklóssy G, Boross P, Weber IT, Tözsér J.  Amino acid preferences of retroviral proteases for amino-terminal positions in a type 1 cleavage site. J Virol. 2008 Oct;82(20):10111-7. Epub 2008 Aug 13.
• Kádas J, Boross P, Weber IT, Bagossi P, Matúz K, Tözsér J. C-terminal residues of mature human T-lymphotropic virus type 1 protease are critical for dimerization and catalytic activity.Biochem J. 2008 Dec 15;416(3):357-64.
• Kakuk A, Friedländer E, Vereb G Jr, Lisboa D, Bagossi P, Tóth G, Gergely P, Vereb G. Nuclear and nucleolar localization signals and their targeting function in phosphatidylinositol 4-kinase PI4K230. Exp Cell Res. 2008 Aug 1;314(13):2376-88. Epub 2008 May 27.
• Csutak A, Silver DM, Tozsér J, Steiber Z, Bagossi P, Hassan Z, Berta A. Plasminogen activator inhibitor in human tears after laser refractive surgery. J Cataract Refract Surg. 2008 Jun;34(6):897-901.
• Miklóssy G, Tözsér J, Kádas J, Ishima R, Louis JM, Bagossi P. Novel macromolecular inhibitors of human immunodeficiency virus-1 protease. Protein Eng Des Sel. 2008 Jul;21(7):453-61. Epub 2008 May 13.
• Menéndez-Arias L, Tözsér J. HIV-1 protease inhibitors: effects on HIV-2 replication and resistance.Trends Pharmacol Sci. 2008 Jan;29(1):42-9. Epub 2007 Dec 4. Review.

2007

• Wang YF, Tie Y, Boross PI, Tozser J, Ghosh AK, Harrison RW, Weber IT. Potent new antiviral compound shows similar inhibition and structural interactions with drug resistant mutants and wild type HIV-1 protease. J Med Chem. 2007 Sep 6;50(18):4509-15. Epub 2007 Aug 16.
• Olivares I, Mulky A, Boross PI, Tözsér J, Kappes JC, López-Galíndez C, Menéndez-Arias L.HIV-1 protease dimer interface mutations that compensate for viral reverse transcriptase instability in infectious virions. J Mol Biol. 2007 Sep 14;372(2):369-81. Epub 2007 Jul 3.
• Sperka T, Miklóssy G, Tie Y, Bagossi P, Zahuczky G, Boross P, Matúz K, Harrison RW, Weber IT, Tözsér J. Bovine leukemia virus protease: comparison with human T-lymphotropic virus and human immunodeficiency virus proteases. J Gen Virol. 2007 Jul;88(Pt 7):2052-63.
• Tözsér J, Weber IT. The protease of human T-cell leukemia virus type-1 is a potential therapeutic target.Curr Pharm Des. 2007;13(12):1285-94. Review.
• Amano M, Koh Y, Das D, Li J, Leschenko S, Wang YF, Boross PI, Weber IT, Ghosh AK, Mitsuya H. A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro.Antimicrob Agents Chemother. 2007 Jun;51(6):2143-55. Epub 2007 Mar 19.
• Varga A, Bagossi P, Tözsér J, Peitl B, Szilvássy Z. Effect of experimental hypercholesterolaemia on K+ channel alpha-subunit mRNA levels in rabbit hearts. Eur J Pharmacol. 2007 May 7;562(1-2):130-1. Epub 2007 Feb 16.
• Tie Y, Kovalevsky AY, Boross P, Wang YF, Ghosh AK, Tozser J, Harrison RW, Weber IT. Atomic resolution crystal structures of HIV-1 protease and mutants V82A and I84V with saquinavir. Proteins. 2007 Apr 1;67(1):232-42.

2006

• Sperka T, Boross P, Eizert H, Tözsér J, Bagossi P. Effect of mutations on the dimer stability and the pH optimum of the human foamy virus protease. Protein Eng Des Sel. 2006 Aug;19(8):369-75. Epub 2006 Jun 24.
• Fang B, Boross PI, Tozser J, Weber IT. Structural and kinetic analysis of caspase-3 reveals role for s5 binding site in substrate recognition. J Mol Biol. 2006 Jul 14;360(3):654-66. Epub 2006 Jun 2.
• Fehér A, Boross P, Sperka T, Miklóssy G, Kádas J, Bagossi P, Oroszlan S, Weber IT, Tözsér J. Characterization of the murine leukemia virus protease and its comparison with the human immunodeficiency virus type 1 protease. J Gen Virol. 2006 May;87(Pt 5):1321-30.
• Liu F, Kovalevsky AY, Louis JM, Boross PI, Wang YF, Harrison RW, Weber IT. Mechanism of drug resistance revealed by the crystal structure of the unliganded HIV-1 protease with F53L mutation. J Mol Biol. 2006 May 19;358(5):1191-9. Epub 2006 Mar 20.
• Tözsér J, Shulenin S, Young MR, Briggs CJ, Oroszlan S. Replication-dependent fitness recovery of Human immunodeficiency virus 1 harbouring mutations of Asn17 of the nucleocapsid protein. J Gen Virol. 2006 Apr;87(Pt 4):961-5.
• Kovalevsky AY, Tie Y, Liu F, Boross PI, Wang YF, Leshchenko S, Ghosh AK, Harrison RW, Weber IT.Effectiveness of nonpeptide clinical inhibitor TMC-114 on HIV-1 protease with highly drug resistant mutations D30N, I50V, and L90M. J Med Chem. 2006 Feb 23;49(4):1379-87.

2005

• Mitchell MS, Tözsér J, Princler G, Lloyd PA, Auth A, Derse D. Synthesis, processing, and composition of the virion-associated HTLV-1 reverse transcriptase. J Biol Chem. 2006 Feb 17;281(7):3964-71. Epub 2005 Dec 19.
• Liu F, Boross PI, Wang YF, Tozser J, Louis JM, Harrison RW, Weber IT. Kinetic, stability, and structural changes in high-resolution crystal structures of HIV-1 protease with drug-resistant mutations L24I, I50V, and G73S. J Mol Biol. 2005 Dec 9;354(4):789-800. Epub 2005 Oct 21.
• Boross P, Tözsér J, Bagossi P. Improved purification protocol for wild-type and mutant human foamy virus proteases.Protein Expr Purif. 2006 Apr;46(2):343-7. Epub 2005 Oct 5.
• Tie Y, Boross PI, Wang YF, Gaddis L, Liu F, Chen X, Tozser J, Harrison RW, WeberIT.Molecular basis for substrate recognition and drug resistance from 1.1 to 1.6 angstroms resolution crystal structures of HIV-1 protease mutants with substrate analogs. FEBS J. 2005 Oct;272(20):5265-77.
• Sperka T, Pitlik J, Bagossi P, Tözsér J. Beta-lactam compounds as apparently uncompetitive inhibitors of HIV-1 protease. Bioorg Med Chem Lett. 2005 Jun 15;15(12):3086-90.
• Bagossi P, Sperka T, Fehér A, Kádas J, Zahuczky G, Miklóssy G, Boross P, Tözsér J. Amino acid preferences for a critical substrate binding subsite of retroviral proteases in type 1 cleavage sites. J Virol. 2005 Apr;79(7):4213-8.
• Tözsér J, Tropea JE, Cherry S, Bagossi P, Copeland TD, Wlodawer A, Waugh DS. Comparison of the substrate specificity of two potyvirus proteases. FEBS J. 2005 Jan;272(2):514-23.
• Bagossi P, Horváth G, Vereb G, Szöllösi J, Tözsér J. Molecular modeling of nearly full-length ErbB2 receptor.Biophys J. 2005 Feb;88(2):1354-63. Epub 2004 Dec 13.

2004

• Nallamsetty S, Kapust RB, Tözsér J, Cherry S, Tropea JE, Copeland TD, Waugh DS. Efficient site-specific processing of fusion proteins by tobacco vein mottling virus protease in vivo and in vitro. Protein Expr Purif. 2004 Nov;38(1):108-15.
• Bagossi P, Kádas J, Miklóssy G, Boross P, Weber IT, Tözsér J. Development of a microtiter plate fluorescent assay for inhibition studies on the HTLV-1 and HIV-1 proteinases. J Virol Methods. 2004 Aug;119(2):87-93.
• Csutak A, Silver DM, Tözsér J, Hassan Z, Berta A. Urokinase-type plasminogen activator to prevent haze after photorefractive keratectomy, and pregnancy as a risk factor for haze in rabbits.Invest Ophthalmol Vis Sci. 2004 May;45(5):1329-33.
• Kádas J, Weber IT, Bagossi P, Miklóssy G, Boross P, Oroszlan S, Tözsér J. Narrow substrate specificity and sensitivity toward ligand-binding site mutations of human T-cell Leukemia virus type 1 protease. J Biol Chem. 2004 Jun 25;279(26):27148-57. Epub 2004 Apr 20.
• Tie Y, Boross PI, Wang YF, Gaddis L, Hussain AK, Leshchenko S, Ghosh AK, Louis JM, Harrison RW, Weber IT. High resolution crystal structures of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017) active against multi-drug-resistant clinical strains. J Mol Biol. 2004 Apr 23;338(2):341-52.
• Mahalingam B, Wang YF, Boross PI, Tozser J, Louis JM, Harrison RW, Weber IT. Crystal structures of HIV protease V82A and L90M mutants reveal changes in the indinavir-binding site.Eur J Biochem. 2004 Apr;271(8):1516-24.
• Tözsér J, Shulenin S, Louis JM, Copeland TD, Oroszlan S. In vitro processing of HIV-1 nucleocapsid protein by the viral proteinase: effects of amino acid substitutions at the scissile bond in the proximal zinc finger sequence.Biochemistry. 2004 Apr 13;43(14):4304-12.
• Fehér A, Boross P, Sperka T, Oroszlan S, Tözsér J. Expression of the murine leukemia virus protease in fusion with maltose-binding protein in Escherichia coli. Protein Expr Purif. 2004 May;35(1):62-8.
• 2003
• Csutak A, Silver DM, Tozsér J, Facskó A, Berta A. Plasminogen activator activity and inhibition in rabbit tears after photorefractive keratectomy. Exp Eye Res. 2003 Dec;77(6):675-80.
• Tözsér J. Stages of HIV replication and targets for therapeutic intervention. Curr Top Med Chem. 2003;3(13):1447-57. Review.
• Koh Y, Nakata H, Maeda K, Ogata H, Bilcer G, Devasamudram T, Kincaid JF, Boross P, Wang YF, Tie Y, Volarath P, Gaddis L, Harrison RW, Weber IT, Ghosh AK, Mitsuya H. Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro. Antimicrob Agents Chemother. 2003 Oct;47(10):3123-9.
• Tözsér J, Oroszlan S. Proteolytic events of HIV-1 replication as targets for therapeutic intervention. Curr Pharm Des. 2003;9(22):1803-15. Review.
• Tözsér J, Shulenin S, Kádas J, Boross P, Bagossi P, Copeland TD, Nair BC, Sarngadharan MG, Oroszlan S. Human immunodeficiency virus type 1 capsid protein is a substrate of the retroviral proteinase while integrase is resistant toward proteolysis. Virology. 2003 May 25;310(1):16-23.
• Tözsér J, Bagossi P, Zahuczky G, Specht SI, Majerova E, Copeland TD. Effect of caspase cleavage-site phosphorylation on proteolysis. Biochem J. 2003 May 15;372(Pt 1):137-43.
• Zeke T, Kókai E, Szöor B, Yatzkan E, Yarden O, Szirák K, Fehér Z, Bagossi P, Gergely P, Dombrádi V. Expression of protein phosphatase 1 during the asexual development of Neurospora crassa. Comp Biochem Physiol B Biochem Mol Biol. 2003 Jan;134(1):161-70.

2002

• Fehér A, Weber IT, Bagossi P, Boross P, Mahalingam B, Louis JM, Copeland TD, Torshin IY, Harrison RW, Tözsér J. Effect of sequence polymorphism and drug resistance on two HIV-1 Gag processing sites.Eur J Biochem. 2002 Aug;269(16):4114-20.
• Kapust RB, Tözsér J, Copeland TD, Waugh DS. The P1' specificity of tobacco etch virus protease.Biochem Biophys Res Commun. 2002 Jun 28;294(5):949-55.
• Mahalingam B, Boross P, Wang YF, Louis JM, Fischer CC, Tozser J, Harrison RW, Weber IT. Combining mutations in HIV-1 protease to understand mechanisms of resistance. Proteins. 2002 Jul 1;48(1):107-16.

2001

• Kapust RB, Tözsér J, Fox JD, Anderson DE, Cherry S, Copeland TD, Waugh DS. Tobacco etch virus protease: mechanism of autolysis and rational design of stable mutants with wild-type catalytic proficiency. Protein Eng. 2001 Dec;14(12):993-1000.
• Tözsér J. HIV inhibitors: problems and reality. Ann N Y Acad Sci. 2001 Nov;946:145-59. Review.
• Ishima R, Ghirlando R, Tözsér J, Gronenborn AM, Torchia DA, Louis JM. Folded monomer of HIV-1 protease. J Biol Chem. 2001 Dec 28;276(52):49110-6. Epub 2001 Oct 11.
• Gáspár R Jr, Bagossi P, Bene L, Matkó J, Szöllosi J, Tozsér J, Fésüs L, Waldmann TA, Damjanovich S. Clustering of class I HLA oligomers with CD8 and TCR: three-dimensional models based on fluorescence resonance energy transfer and crystallographic data. J Immunol. 2001 Apr 15;166(8):5078-86.

2000

• Csutak A, Tözsér J, Békési L, Hassan Z, Berta A, Silver DM. Plasminogen activator activity in tears after excimer laser photorefractive keratectomy. Invest Ophthalmol Vis Sci. 2000 Nov;41(12):3743-7.
• Louis JM, Weber IT, Tözsér J, Clore GM, Gronenborn AM. HIV-1 protease: maturation, enzyme specificity, and drug resistance. Adv Pharmacol. 2000;49:111-46. Review.
• Tözsér J, Zahuczky G, Bagossi P, Louis JM, Copeland TD, Oroszlan S, Harrison RW, Weber IT. Comparison of the substrate specificity of the human T-cell leukemia virus and human immunodeficiency virus proteinases. Eur J Biochem. 2000 Oct;267(20):6287-95.
• Tözsér J, Berta A. Lactate dehydrogenase activity in pathological human tears obtained with glass capillaries correlates with the albumin content. Int Ophthalmol. 1998;22(5):289-92.
• Zahuczky G, Boross P, Bagossi P, Emri G, Copeland TD, Oroszlan S, Louis JM, Tözsér J. Cloning of the bovine leukemia virus proteinase in Escherichia coli and comparison of its specificity to that of human T-cell leukemia virus proteinase. Biochim Biophys Acta. 2000 Mar 16;1478(1):1-8.

1999

• Fenyöfalvi G, Bagossi P, Copeland TD, Oroszlan S, Boross P, Tözsér J. Expression and characterization of human foamy virus proteinase. FEBS Lett. 1999 Dec 3;462(3):397-401.
• Briggs CJ, Ott DE, Coren LV, Oroszlan S, Tözsér J.  Comparison of the effect of FK506 and cyclosporin A on virus production in H9 cells chronically and newly infected by HIV-1. Arch Virol. 1999;144(11):2151-60.
• Skuta G, Fischer GM, Janaky T, Kele Z, Szabo P, Tozser J, Sumegi B. Molecular mechanism of the short-term cardiotoxicity caused by 2',3'-dideoxycytidine (ddC): modulation of reactive oxygen species levels and ADP-ribosylation reactions. Biochem Pharmacol. 1999 Dec 15;58(12):1915-25.
• Tözsér J, Bagossi P, Boross P, Louis JM, Majerova E, Oroszlan S, Copeland TD. Effect of serine and tyrosine phosphorylation on retroviral proteinase substrates. Eur J Biochem. 1999 Oct 1;265(1):423-9.
• Boross P, Bagossi P, Copeland TD, Oroszlan S, Louis JM, Tözsér J. Effect of substrate residues on the P2' preference of retroviral proteinases. Eur J Biochem. 1999 Sep;264(3):921-9.
• Louis JM, Oroszlan S, Tözsér J. Stabilization from autoproteolysis and kinetic characterization of the human T-cell leukemia virus type 1 proteinase. J Biol Chem. 1999 Mar 5;274(10):6660-6.
• 1998
• Vissi E, Tóth EC, Kovács I, Magyar Z, Horváth GV, Bagossi P, Gergely P, Dudits D, Dombrádi V. Protein phosphatase 1 catalytic subunit isoforms from alfalfa: biochemical characterization and cDNA cloning.Arch Biochem Biophys. 1998 Dec 15;360(2):206-14.
• Bagossi P, Cheng YS, Oroszlan S, Tözsér J. Comparison of the specificity of homo- and heterodimeric linked HIV-1 and HIV-2 proteinase dimers. Protein Eng. 1998 Jun;11(6):439-45.
• Takács L, Boross P, Tözser J, Módis L Jr, Tóth G, Berta A. Transforming growth factor-beta induced protein, betaIG-H3, is present in degraded form and altered localization in lattice corneal dystrophy type I. Exp Eye Res. 1998 Jun;66(6):739-45.

1997

• Nemes Z Jr, Adány R, Balázs M, Boross P, Fésüs L. Identification of cytoplasmic actin as an abundant glutaminyl substrate for tissue transglutaminase in HL-60 and U937 cells undergoing apoptosis. J Biol Chem. 1997 Aug 15;272(33):20577-83.
• Tözsér J, Bagossi P, Weber IT, Louis JM, Copeland TD, Oroszlan S. Studies on the symmetry and sequence context dependence of the HIV-1 proteinase specificity. J Biol Chem. 1997 Jul 4;272(27):16807-14.
• Tözsér J, Yin FH, Cheng YS, Bagossi P, Weber IT, Harrison RW, Oroszlan S. Activity of tethered human immunodeficiency virus 1 protease containing mutations in the flap region of one subunit. Eur J Biochem. 1997 Feb 15;244(1):235-41.
• Tözsér J. Specificity of Retroviral Proteinases Based on Substrates Containing Tyrosine and Proline at the Site of Cleavage. Pathol Oncol Res. 1997;3(2):142-146.

1996

• Briggs CJ, Tözsér J, Oroszlan S. Effect of cyclosporin A on the replication cycle of human immunodeficiency virus type 1 derived from H9 and Molt-4 producer cells. J Gen Virol. 1996 Dec;77 ( Pt 12):2963-7.
• Bagossi P, Cheng YS, Oroszlan S, Tözsér J. Activity of linked HIV-1 proteinase dimers containing mutations in the active site region. Protein Eng. 1996 Nov;9(11):997-1003.
• Tözsér J, Bagossi P, Weber IT, Copeland TD, Oroszlan S. Comparative studies on the substrate specificity of avian myeloblastosis virus proteinase and lentiviral proteinases. J Biol Chem. 1996 Mar 22;271(12):6781-8.
• Bogáti MS, Pócsi I, Maticsek J, Boross P, Tözsér J, Szentirmai A. NADP-specific glutamate dehydrogenase of Penicillium chrysogenum has a homohexamer structure. J Basic Microbiol. 1996;36(5):371-5.

1993

• Weber IT, Tözsér J, Wu J, Friedman D, Oroszlan S. Molecular model of equine infectious anemia virus proteinase and kinetic measurements for peptide substrates with single amino acid substitutions.Biochemistry. 1993 Apr 6;32(13):3354-62.
• Tözsér J, Friedman D, Weber IT, Bláha I, Oroszlan S. Studies on the substrate specificity of the proteinase of equine infectious anemia virus using oligopeptide substrates. Biochemistry. 1993 Apr 6;32(13):3347-53.

1992

• Bláha I, Tözsér J, Kim Y, Copeland TD, Oroszlan S. Solid phase synthesis of the proteinase of bovine leukemia virus. Comparison of its specificity to that of HIV-2 proteinase. FEBS Lett. 1992 Sep 14;309(3):389-93.
• Tözsér J, Weber IT, Gustchina A, Bláha I, Copeland TD, Louis JM, Oroszlan S. Kinetic and modeling studies of S3-S3' subsites of HIV proteinases. Biochemistry. 1992 May 26;31(20):4793-800.

1991

• Bláha I, Nemec J, Tözsér J, Oroszlan S. Synthesis of homologous peptides using fragment condensation: analogs of an HIV proteinase substrate. Int J Pept Protein Res. 1991 Nov;38(5):453-8.
• Tözsér J, Berta A. Plasminogen activator inhibitors in human tears. Acta Ophthalmol (Copenh). 1991 Aug;69(4):426-31.
• Tözsér J, Bláha I, Copeland TD, Wondrak EM, Oroszlan S. Comparison of the HIV-1 and HIV-2 proteinases using oligopeptide substrates representing cleavage sites in Gag and Gag-Pol polyproteins.FEBS Lett. 1991 Apr 9;281(1-2):77-80.
• Tözsér J, Gustchina A, Weber IT, Blaha I, Wondrak EM, Oroszlan S. Studies on the role of the S4 substrate binding site of HIV proteinases. FEBS Lett. 1991 Feb 25;279(2):356-60.

1990

• Berta A, Tözsér J, Holly FJ. Determination of plasminogen activator activities in normal and pathological human tears. The significance of tear plasminogen activators in the inflammatory and traumatic lesions of the cornea and the conjunctiva. Acta Ophthalmol (Copenh). 1990 Oct;68(5):508-14.
• Tözsér J, Berta A. Urokinase-type plasminogen activator in rabbit tears. Comparison with human tears.Exp Eye Res. 1990 Jul;51(1):33-7.
• Copeland TD, Wondrak EM, Tozser J, Roberts MM, Oroszlan S. Substitution of proline with pipecolic acid at the scissile bond converts a peptide substrate of HIV proteinase into a selective inhibitor. Biochem Biophys Res Commun. 1990 May 31;169(1):310-4.
• Tözsér J, Marsalkó TM, Punyiczki M, Elödi P. The enzyme capable to cleave trypsin active site titrant as substrate is a carboxylesterase with electrophoretic mobility similar to albumin. Acta Biochim Biophys Hung. 1990;25(1-2):57-65.

1989

• Tözsér J, Berta A, Punyiczki M. Plasminogen activator activity and plasminogen independent amidolytic activity in tear fluid from healthy persons and patients with anterior segment inflammation. Clin Chim Acta. 1989 Aug 31;183(3):323-31.
• Tözsér J, Hamvas A, Rády P, Kertai P, Elödi P. Plasminogen activator and plasmin-like activities in experimental rat tumours. Acta Biochim Biophys Hung. 1989;24(1-2):119-28.